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Influence of bisphosphonates on alveolar 
bone density: a histomorphometric 
analysis
Abstract: This study is a histomorphometrical analysis of the influence 
of the bisphosphonate alendronate on alveolar bone density. Eighteen 
male Wistar rats were randomly assigned to a control group (n = 9) that 
received no medication and an experimental group (n = 9) that received 
oral alendronate (1 mg/kg) from birth until euthanization at 3 months of 
age. Semi-serial 4-µm-thick transverse sections were obtained from the 
region between the roots of the left maxillary first molar, stained with 
hematoxylin and eosin, and examined with a Zeiss Axioskop II optical 
microscope for histomorphometric analysis. The images were captured 
with a digital camera coupled with the microscope and connected to a 
computer, and were analyzed using Image J 1.34s image-analysis soft-
ware. A 1,200-point grid was positioned onto each digitized image. The 
number of intersection points of grid lines in the bone tissue was count-
ed. The ratio between the number of points in the bone tissue and the to-
tal number of points of the grid (1,200) was used to determine the bone 
density of the analyzed tissue. Data from the control and experimental 
groups were compared and analyzed statistically by the Student’s t-test 
(p = 0.05). There was no statistically significant difference (p = 0.3754) 
in the alveolar bone density between the control and alendronate-treated 
animals. It may be concluded that the bisphosphonate alendronate did 
not alter the morphology of the alveolar bone, maintaining its structural 
tissue characteristics in healthy animals.
Descriptors: Diphosphonates; Alendronate; Bone density; Alveolar 
bone loss.
Introduction
Pyrophosphates (P-O-P), bisphosphonates precursors, have been 
known to chemists since the 19th century, the first synthesis dating back 
to 1865 in Germany.1 The initial uses for pyrophosphates and bisphos-
phonates in industry were as antiscaling and anticorrosive agents, emol-
lients for the prevention of calcium carbonate precipitation in metallic 
plumbing. An expanded understanding of bone physiology, as well as a 
growing appreciation of bisphosphonate chemistry, allowed a broaden-
ing range of clinical applications. Further research showed that bisphos-
phonates were effective in controlling calcium phosphate formation and 
dissolution in vitro as well as bone resorption and mineralization in vivo, 
extending its therapeutic use for the treatment of innumerous diseases. 
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Pyrophosphates are physiological regulators of cal-
cification and bone resorption, which are naturally 
present in the serum and urine. Bisphosphonates 
are structural analogs of pyrophosphates and their 
mechanism of action is similar to that of the afore-
mentioned compounds.1
The discovery that bisphosphonates have potent 
inhibitory effects on bone resorption occurred in the 
1960’s,2,3 after several attempts to identify agents 
that were pyrophosphate analogs and could also 
regulate bone calcification, thus being potentially 
useful for the prevention of osteoporosis, arthritis, 
osteolytic diseases and bone metastases resulting 
from malignant neoplasias.
Alendronate, clodronate, pamidronate and zole-
dronate are some of the bisphosphonates used for 
the treatment of bone diseases.4,5 Each drug pres-
ents a peculiar physicochemical structure and spe-
cific biological functions, which mean that the re-
sults of experimental evaluations obtained for one 
bisphosphonate cannot be extrapolated to another.4 
The use of bisphosphonate drugs by patients with 
Paget’s disease decreases bone turnover, reducing 
bone loss.4,5 The administration of bisphosphonates 
to patients with metastases has been shown to sig-
nificantly reduce the occurrence of bone fractures, 
malignant hypocalcaemia, need of radiotherapy and 
bone surgery due to neoplasic tumors.6,7,8
Bisphosphonates that contain nitrogen, such as 
alendronate, have been shown to be more potent in-
hibitors of bone resorption in vivo than those that 
do not have this chemical element in their compo-
sition.9 These nitrogen-containing bisphosphonates 
reduce the recruitment of clastic cells and induce 
osteoblasts to produce an inhibitory factor to osteo-
clast formation.10,11 In addition, the action of alen-
dronate induces osteoclast apoptosis and reduces 
the participation of these cells in bone resorption 
(Figure 1). Alendronate is widely used in medicine 
in the control of osteopenia, preventing osteoporo-
sis and the occurrence of fractures in women with 
postmenopausal osteoporosis.12,13
The use of bisphosphonates has increasingly 
gained the attention of dental professionals. The 
clinical protocols for the treatment of dental pa-
tients under bisphosphonate therapy in order to pre-
vent the occurrence of postoperative complications, 
such as osteomyelites,8 after surgical periodontal 
procedures, extractions or implant placement, and 
delay of tooth movement during orthodontic treat-
ment has been discussed in literature. Older patients 
are more commonly seeking dental offices with both 
functional and esthetic demands. Many of these 
patients, however, have systemic conditions that re-
quire long-term use of certain medications, such as 
bisphosphonates. It is certainly not uncommon that 
postmenopausal female patients undergoing therapy 
with oral alendronate, for example, attend dental 
offices without the dentist being made aware of their 
drug therapy. 
It is possible that the prolonged use of alendro-
nate increases the alveolar bone density and this 
structural alteration could play a role in reducing 
the repair capacity of the alveolar bone tissue in 
response to different dental procedures. Therefore, 
this study histomorphometrically analyzed the influ-
ence of alendronate on alveolar bone density in the 
maxilla of rats treated with this bisphosphonate.
Material and Methods
Eighteen 90-day-old male Wistar rats (Rattus 
norvegicus albinus) with initial mean weight of 
300 g were obtained from the vivarium of Bauru 
Dental School, São Paulo State University, Brazil af-
Figure 1 - Osteoclast in apoptosis (arrow) close to a con-
gested vessel found in some animals of the alendronate-
treated group. Note the chromatin condensation and loss 
of nuclear polarization (Hematoxylin and eosin - HE; ×1000 
magnification).
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ter approval of the research protocol by the institu-
tional Animal Care and Research Use Committee. 
All guidelines regarding the care of animal research 
subjects were strictly followed in this study. The 
animals were housed in cages and maintained in a 
clean, ventilated environment with natural lighting 
and a mean temperature of 25oC,14 and were fed 
standard rat chow (Guabi; Nutrilabor, Campinas, 
SP, Brazil) and water ad libitum during the entire 
experimental period.
The animals were randomly assigned to a con-
trol group (n = 9), which did not receive any medi-
cation, and an experimental group (n = 9) to which 
oral sodium alendronate (Alendil; Farmoquímica, 
Rio de Janeiro, RJ, Brazil) was administrated twice 
a week15 at the same time of day with 3 day intervals 
between the doses. The bisphosphonate was admin-
istered to the rats from birth until euthanization. 
The drug was fractionated to obtain a dose compat-
ible to the dose given to human patients (1 mg/kg) 
and was administered by gavage as a solution us-
ing syringes coupled with 7 cm urethral catheters. 
The cannula of the catheter was easily introduced 
through the throat of the rat without the risk of re-
gurgitation of the medication. 
The animals were euthanized at 3 months of 
age with a lethal injection of a mixture of ketamine 
hydrochloride (Dopalen – 100 mg/ml; Vetbrands, 
Jacareí, SP, Brazil) and xylazine hydrochloride 
(Anasedan – 20 mg/ml; Vetbrands, Jacareí, SP, Bra-
zil), followed by decapitation and dissection of the 
epithelial and muscular tissues circumjacent to the 
maxilla. The maxillas were fixed in buffered 10% 
formalin within 48 hours of the euthanization of 
the animals, demineralized in Morse solution (equal 
volumes of sodium solution and formic acid) within 
7 days of the euthanization of the animals and em-
bedded in paraffin. Semi-serial 4-µm-thick transver-
sal sections were obtained, stained with hematoxy-
lin and eosin, and examined with a Zeiss Axioskop 
II optical microscope (Carl Zeiss AG, Oberkochen, 
Germany) with a ×10 magnification objective lens 
(Carl Zeiss AG, Oberkochen, Germany) for histo-
morphometric analysis. The medullar alveolar bone 
between the roots of the left maxillary first molar at 
the cervical third was evaluated. The images were 
captured with a digital camera (CCD IRIS/RGB, 
Sony Corp., Tokyo, Japan) coupled with the micro-
scope and connected to a computer and were ana-
lyzed using Image J 1.34s image-analysis software 
(National Institute of Health, Bethesda, Mary-
land, USA). A 1,200-point grid with a total area of 
694 x 520 µm was positioned onto each digitized 
image. The number of intersection points of the hor-
izontal and vertical lines of the grid on the image 
of the bone tissue (not in the medullar spaces) was 
counted. The ratio between the number of points in 
the bone tissue and the total number of points of the 
grid (1,200) allowed for the determination of the 
bone density of the analyzed tissue (Figure 2).
The bone density data from the control and alen-
dronate-treated groups were compared and statisti-
cally analyzed by the Student’s t-test at 5% signifi-
cance level using SAS software (v.3.43; SAS Institute 
Inc., Cary, North Carolina, USA). 
Results
The mean bone density values for each ani-
mal and for each group are represented in Table 
1. There was no statistically significant difference 
(p = 0.3754) in the alveolar bone density between 
the control and alendronate-treated animals (Table 
1 and Graph 1). The groups were homogeneous with 
an F = 0.89 (homogeneity is considered if F > 0.05).
Figure 2 - 1,200-point grid positioned onto each digitized 
image of a histological section. The number of intersection 
points of the horizontal and vertical lines of the grid in the 
bone tissue (not in the medullar spaces) was counted. (He-
matoxylin and eosin - HE; ×100 magnification).
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Discussion
The effects of the bisphosphonates occur at both 
tissue and cellular levels.4 At a tissue level, these 
compounds promote a decrease of bone turnover,4 as 
demonstrated by biochemical markers,16,17,18 show-
ing a reduction in the extension of the bone resorp-
tion areas and the depth of the resorbed areas. At 
a cellular level, bisphosphonates act inhibiting the 
activity and recruitment of osteoclasts to the bone 
surface, inducing the apoptosis of these cells and al-
tering the mineral exchange.4 The bisphosphonates 
incorporated into the bone are released in How-
ship’s lacunae and internalized in the osteoclasts by 
endocytosis, affecting these cells directly. After this 
phenomenon, the osteoclasts lose their ruffled bor-
der and their cytoskeleton is progressively disrupt-
ed, inactivating the resorptive activity of these cells 
and inducing apoptosis (Figure 1).19 This process is 
due to the inhibition of the enzyme farnesyl diphos-
phate synthase,20,21 especially by the administration 
of nitrogen-containing bisphosphonates, such as 
alendronate. This enzyme is necessary for the pre-
nylation of small GTPases,22 which are responsible 
for the signaling proteins that control morphology, 
cytoskeleton arrangement, ruffled borders, vesicle 
transportation and apoptosis of osteoclasts.23
It is known that the systemic effects of bisphos-
phonates are not immediate4 and that, in spite of 
their recognized inhibitory effect of calcification in 
vitro, a prolonged administration of these drugs is 
necessary to produce an effective inhibition of bone 
resorption. 
Bisphosphonates are incorporated into miner-
alized structures. After bone uptake, the bisphos-
phonates are liberated again only when the bone in 
which they are deposited is resorbed. Under patho-
logical conditions, alveolar bone loss is related to 
alterations in the normal balance between bone for-
mation and resorption. Therapeutic agents that are 
capable of avoiding bone resorption and accelera-
tion of bone deposition may act in preventing bone 
loss in patients with conditions such as periodontal 
disease.
The effects of bisphosphonates in controlling 
alveolar bone loss in advanced periodontal disease 
and their action in the inflammatory processes asso-
ciated with periodontal breakdown have been inves-
tigated in rat experimental models.24 The effects of 
bisphosphonates in controlling alveolar bone loss in 
advanced periodontal disease and their action in the 
inflammatory processes associated with periodontal 
breakdown have also been examined with the induc-
tion of periodontal disease by Porphyromonas gingi-
valis25 in monkeys26 and dogs.27 The results of these 
studies confirm that bisphosphonates were more 
effective preventing alveolar bone loss in animals 
with experimentally induced periodontal disease. 
When large bone tissue destruction was present, the 
groups treated with bisphosphonates exhibited less 
bone loss and a greater amount of remaining alveo-
Table 1 - Mean bone density values (bone areas/non-bone areas ratio) in each animal and each group.
Group 1 2 3 4 5 6 7 8 9 Total
Control 92.22 81.43 85.31 72.21 77.10 76.86 83.56 59.49 83.28 79.05 ± 9.31
Alendronate 73.70 61.87 79.96 84.67 82.08 61.94 79.30 64.80 86.24 74.95 ± 9.75
Bo
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Graph 1 - Mean values of bone density and standard devi-
ations for the control and alendronate-treated groups. Bone 
density was determined as the ratio between the number of 
points in the bone tissue and the total number of points of 
the grid (1,200). p = 0.3754 (Student’s t-test).
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lar bone. However, the microscopic results showed 
no differences in the mandibles of the animals with 
little or no periodontal disease compared to the 
healthy control animals. In the same way, a previous 
study evaluating the post-extraction bone repair in 
rat teeth showed that the administration of dichlo-
romethylene bisphosphonate (clodronate) inhibited 
the occurrence of rapid alveolar bone loss after ex-
traction. This effect was observed exclusively in the 
surgical wounds and no differences were found be-
tween control and experimental animals in the in-
tact bone areas.28
In this way, studies investigating the effects of 
bisphosphonates on inflammatory process and al-
veolar repair seem to demonstrate that these drugs 
do not microscopically alter the bone structure in 
healthy areas, corroborating the results of the pres-
ent study in which no difference was found in the 
bone density of control and experimental animals 
(Table 1 and Graph 1). Bisphosphonates bind pref-
erentially to bones that have high turnover rates, 
and their distribution in the bone tissue is not ho-
mogeneous.4,5 Therefore, it may be inferred that 
the incorporation of bisphosphonates to maxillary 
bones with no pathological processes would provide 
a longer period of time for a structural organiza-
tion, without compromising or altering their archi-
tecture.
The analysis by light microscopy did not show 
any effects of the alendronate on the composition 
of the mineralized bone matrix in either the control 
or experimental groups. Morphologically, the char-
acteristics of the bone tissue were similar in both 
groups with respect to the distribution and number 
of reversion lines, proportion of medullar spaces, 
bone trabeculae and cortical bone. Similar distribu-
tion and number of osteoclasts and bone remodeling 
units in the analyzed bone structures was also ob-
served in both groups (Figure 3). 
The therapeutic effects of bisphosphonates do 
not depend on the inhibition of normal bone re-
modeling, but is associated, rather, with pathologi-
cal bone resorption or with regions with high bone 
turnover.29 Therefore, based on the findings of the 
present study, no complications in dental treatments, 
such as orthodontic movement, dental extractions 
or implant placement, are expected because these 
procedures are usually performed in healthy bone 
tissue.16
In the present study, there was no difference in 
the bone density between the animals that received 
alendronate and the non-treated control animals. It 
was not possible to determine, using optical micros-
copy, any effect of the drug in the composition of 
the mineralized bone matrix in either of the groups. 
Morphologically, the alveolar bone in the animals 
Figure 3 - Alveolar bone in the alendronate-treated (A) and control (B) group. The bone tissue characteristics were similar in 
both groups with respect to the distribution and number of reversion lines, and proportion of medullar spaces, bone trabeculae 
and cortical bone. The distribution and number of osteoclasts and bone remodeling units in the analyzed bone structures was 
also similar in both groups (Hematoxylin and eosin - HE; ×40 magnification).
A B
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treated with alendronate had the same proportions 
of medullar spaces and bone trabeculae as those of 
the control animals. 
Conclusion
No statistically significant difference in alveo-
lar bone density between the animals that received 
bisphosphonate (alendronate) and control animals 
was found. 
Histomorphometric analysis using an optical mi-
croscope was unable to determine any effect of so-
dium alendronate in the composition of mineralized 
bone matrix between the control and experimental 
groups. Morphologically, the bone in the experi-
mental and control groups showed comparatively 
the same proportion between medullar spaces and 
bone tissue.
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